Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market
Ascletis Pharma, a China-based biotechnology company, is raising up to USD 300 million to listing on the Hong Kong Stock Exchange. Ascletis is the...
822 Views
𝛼SK or SearchENTITY
Ascletis Pharma (1672 HK)
Ascletis Pharma (1672 HK)
112
Analysis
Health Care • China
Ascletis Pharma is a fully integrated biotechnology company focused on the research, development, production, marketing, and sale of innovative pharmaceutical products. The company's marketed products include Ritonavir tablets, GANOVO®, and ASCLEVIR® for Hepatitis C, and it has a robust pipeline primarily in metabolic diseases, viral diseases, and oncology. Ascletis Pharma is headquartered in Hangzhou, China, and was founded in 2011.
morex